Ellen K Kick

List of Publications by Year
in descending order

17	735	687363 13	888059 17
papers	citations	h-index	g-index

17	17	17	909
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chemistry and Biology, 1997, 4, 297-307.	6.0	146
2	Expedient Method for the Solid-Phase Synthesis of Aspartic Acid Protease Inhibitors Directed toward the Generation of Libraries. Journal of Medicinal Chemistry, 1995, 38, 1427-1430.	6.4	144
3	Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metabolism, 2016, 24, 223-233.	16.2	109
4	General Solid-Phase Synthesis Approach To Prepare Mechanism-Based Aspartyl Protease Inhibitor Libraries. Identification of Potent Cathepsin D Inhibitors. Journal of the American Chemical Society, 1998, 120, 9735-9747.	13.7	63
5	Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure. Journal of Medicinal Chemistry, 2020, 63, 9003-9019.	6.4	45
6	Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRÎ². Bioorganic and Medicinal Chemistry Letters, 2015, 25, 372-377.	2.2	35
7	Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor AgonistÂTreatment. JACC Basic To Translational Science, 2019, 4, 905-920.	4.1	32
8	Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRÎ±Activity and a Favorable Window in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 305-314.	2.5	30
9	Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction. JACC Basic To Translational Science, 2021, 6, 676-689.	4.1	26
10	Discovery of Highly Potent Liver X Receptor Î² Agonists. ACS Medicinal Chemistry Letters, 2016, 7, 1207-1212.	2.8	21
11	Identification of novel functional inhibitors of 17Î²-hydroxysteroid dehydrogenase type III (17Î²-HSD3). Prostate, 2005, 65, 159-170.	2.3	20
12	Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. MedChemComm, 2017, 8, 2093-2099.	3.4	19
13	Potent Triazolopyridine Myeloperoxidase Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 1175-1180.	2.8	16
14	Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase. Bioorganic and Medicinal Chemistry, 2020, 28, 115723.	3.0	14
15	Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO). Bioorganic and Medicinal Chemistry Letters, 2021, 42, 128010.	2.2	9
16	Enzymatic resolution of methyl (1RS)-N-tBoc-6-hydroxy-3,4-dihydro-1H-isoquinoline-1-carboxylate by Seaprose S. Tetrahedron: Asymmetry, 2007, 18, 2147-2154.	1.8	5
17	Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists. ACS Medicinal Chemistry Letters, 2022, 13, 943-948.	2.8	1